VIP Peptide Guide: Dosage, Reconstitution, Benefits & Protocol
VIP Peptide (Vasoactive Intestinal Peptide)
VIP (Vasoactive Intestinal Peptide) is a naturally occurring neuropeptide involved in vascular, immune, gastrointestinal, respiratory, and nervous-system signaling. Synthetic VIP has also been studied clinically in several pulmonary and inflammatory conditions. In peptide communities, VIP is additionally discussed in relation to neuroimmune regulation, chronic inflammatory conditions, and CIRS/mold-related protocols, although evidence for these uses varies considerably.
How VIP Works
VIP Signaling → Inflammation ↓ → Immune Regulation ↑ → Nervous System Balance ↑
VIP interacts with receptors throughout the nervous system, lungs, gut, immune system, and vascular tissue. It is commonly studied for regulating inflammatory signaling, supporting vasodilation, calming immune overactivation, and improving neuroimmune communication.
Supports anti-inflammatory signaling pathways
Influences cytokine and immune-system regulation
Promotes vasodilation and circulation support
May support respiratory and gut signaling pathways
VIP Research Protocol (Gradual Approach)
Research context
There is no established clinical subcutaneous VIP dosing protocol for general wellness, inflammation, gut, or neuroimmune use. The ranges below reflect community-discussed research approaches rather than an FDA-approved or clinically standardized dosing schedule. Published human VIP/aviptadil studies have used different routes and dosing methods, including inhaled and intravenous administration.
There is no established clinical subcutaneous VIP dosing protocol for general wellness, inflammation, gut, or neuroimmune use. The ranges below reflect community-discussed research approaches rather than an FDA-approved or clinically standardized dosing schedule. Published human VIP/aviptadil studies have used different routes and dosing methods, including inhaled and intravenous administration.
Low Dose → Receptor Adaptation → Nervous-System Regulation → Full Response
Standard Research Setup
Vial10 mg
Water10 mL bacteriostatic water
Concentration1 mg/mL
Conversion1 unit = 10 mcg
Weeks 1–2
Start Low
Dose50 mcg
Units5 units
Volume0.05 mL
Frequency1× daily
Weeks 3–4
Build Phase
Dose100 mcg
Units10 units
Volume0.10 mL
Frequency1–2× daily
Weeks 5–8+
Full Protocol
Dose150–200 mcg
Units15–20 units
Volume0.15–0.20 mL
Frequency1–2× daily
Protocol Details
Typical Range50–200 mcg daily
Use StyleGradual escalation preferred
AdministrationSubQ or intranasal
Why gradual titration matters
VIP can strongly influence vascular tone, inflammatory signaling, and nervous-system regulation. Starting low may improve tolerance and reduce overstimulation or headaches.
VIP can strongly influence vascular tone, inflammatory signaling, and nervous-system regulation. Starting low may improve tolerance and reduce overstimulation or headaches.
How to Use VIP (Cycle, Timing & Injection)
VPAC Activation → cAMP Signaling → Immune Modulation → Nervous System & Vascular Regulation
Administration Methods
Community ResearchSubcutaneous injection
Research/Clinical LiteratureIntranasal delivery
Injection AreasAbdomen or thigh
GoalConsistent systemic signaling
Research Timing Notes
Morning dosing is commonly preferred.
Some protocols split AM + PM dosing.
Late-night dosing may feel overstimulating for some individuals.
Consistent timing improves protocol stability.
Research Cycle Structure
Typical Research Cycle4–12 weeks
Longer Research CyclesUsed cautiously
Research BreaksOften reassessed every 8–12 weeks
Simple strategy
VIP is usually discussed as a regulation-focused peptide rather than an aggressive “more is better” compound. Consistency and gradual escalation are typically favored over rapid increases.
VIP is usually discussed as a regulation-focused peptide rather than an aggressive “more is better” compound. Consistency and gradual escalation are typically favored over rapid increases.
Reconstitution & Dosing (10 mg Vial)
Accurate Reconstitution → Stable Dosing → Better Tolerance → Consistent Signaling
Vial10 mg
Water10 mL bacteriostatic
Concentration1 mg/mL
Conversion1 unit = 10 mcg
Dose Reference
5 units = 50 mcg
10 units = 100 mcg
15 units = 150 mcg
20 units = 200 mcg
Reconstitution Steps
Draw 10 mL bacteriostatic water
Inject slowly down vial wall
Gently swirl, do not shake
Allow solution to fully dissolve
Refrigerate immediately after mixing
Protect from light and heat
Storage & Shelf Life
Storage & Stability
Lyophilized (Unmixed)
Refrigerate short-term at 2–8°C / 36–46°F
Freeze long-term at −20°C / −4°F
Protect from moisture and heat exposure
Reconstituted (Mixed)
Store refrigerated at 2–8°C / 36–46°F
Best used within ~30 days
Avoid repeated warming cycles
Discard if cloudy or discolored
Why VIP Is Different
Neuroimmune Regulation → Cytokine Balance → Nervous-System Support → Systemic Effects
VIP is not primarily a muscle-building peptide.
It is discussed more for regulation than stimulation.
Its effects involve immune, vascular, respiratory, and nervous-system pathways.
Often discussed in chronic inflammatory or neuroimmune protocols.
Key distinction
VIP is commonly viewed as a “regulatory” peptide focused on restoring balance rather than aggressively forcing a single pathway.
VIP is commonly viewed as a “regulatory” peptide focused on restoring balance rather than aggressively forcing a single pathway.
What Human Research Has Studied
Human Research
VIP has been administered to humans in clinical research for decades.
Synthetic VIP, called aviptadil, has been studied using inhaled and intravenous administration.
Research has included pulmonary hypertension, respiratory disease, vascular effects, and inflammatory signaling.
Human studies confirm that VIP can affect blood vessels, circulation, heart rate, and other physiologic responses.
This research does not establish a standard subcutaneous VIP protocol for general wellness or neuroimmune use.
Important distinction
VIP has legitimate human clinical research behind it, but that does not mean every protocol discussed in peptide communities has been clinically tested. Much of the current SubQ wellness-style use is extrapolated from VIP biology, preclinical research, and community practice rather than standardized clinical dosing.
VIP has legitimate human clinical research behind it, but that does not mean every protocol discussed in peptide communities has been clinically tested. Much of the current SubQ wellness-style use is extrapolated from VIP biology, preclinical research, and community practice rather than standardized clinical dosing.
Monitoring During Use
Energy and nervous-system response
Headache or vascular sensitivity
Inflammatory symptom changes
Respiratory comfort and tolerance
Sleep quality and stress response
Digestive and gut response
Benefits
Supports anti-inflammatory signaling
May improve neuroimmune regulation
Supports circulation and vasodilation
May support respiratory pathways
Potential nervous-system calming effects
Gut and immune signaling support
Potential Side Effects
Headache or flushing
Lightheadedness from vasodilation
Temporary fatigue or overstimulation
Injection-site irritation
Nasal irritation with intranasal use
Limited long-term human data
Research Stacking Strategies
VIP → Neuroimmune Regulation
BPC-157 → Tissue & Gut Support
KPV → Inflammatory Modulation
BPC-157 → Tissue & Gut Support
KPV → Inflammatory Modulation
Community-Discussed Pairings
Inflammation Support: VIP + KPV
Gut-Focused: VIP + BPC-157
Advanced Neuroimmune: VIP + Selank or Semax
Stacking Logic
VIP is often discussed for systemic regulation.
KPV may complement inflammatory-pathway support.
BPC-157 may add tissue and gut-focused support.
Semax or Selank are sometimes paired for nervous-system protocols.
Evidence note
These combinations are discussed in peptide research communities based on potentially complementary pathways. They have not been established as clinically validated combination protocols.
These combinations are discussed in peptide research communities based on potentially complementary pathways. They have not been established as clinically validated combination protocols.
Important Notes
VIP is highly active even at low doses.
Starting conservatively is commonly preferred.
Often discussed in neuroimmune or inflammatory research settings.
May feel stimulating or calming depending on individual response.
Long-term human research remains limited.
Important Disclaimer
VIP is an investigational peptide and not FDA-approved for most uses. This content is for educational purposes only and does not constitute medical advice.
Research & References
Primary Research
- Said SI, Mutt V. Polypeptide with Broad Biological Activity: Isolation from Small Intestine. Science. 1970.
- Delgado M, Pozo D, Ganea D. The Significance of Vasoactive Intestinal Peptide in Immunomodulation. Pharmacological Reviews. 2004;56(2):249-290.
- Delgado M, Ganea D. Vasoactive Intestinal Peptide: A Neuropeptide with Pleiotropic Immune Functions. Amino Acids. 2013;45(1):25-39.
Reviews & Supporting Research
- Ganea D, Hooper KM, Kong W. The Neuropeptide Vasoactive Intestinal Peptide: Direct Effects on Immune Cells and Involvement in Inflammatory and Autoimmune Diseases. Acta Physiologica. 2015;213(2):442-452.
- Harmar AJ, Fahrenkrug J, Gozes I, et al. Pharmacology and Functions of Receptors for Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide: IUPHAR Review 1. British Journal of Pharmacology. 2012;166(1):4-17.
Research Note: Dosing protocols for VIP are drawn from general peptide-handling practice and investigational research settings rather than a standardized clinical dosing regimen, since VIP is not FDA-approved for the uses discussed here.
Comments
Post a Comment